scholarly journals Statin and Spirulina: Will it be an Effective combination in Management of Type 2 Diabetes and it’s Complications

2020 ◽  
Vol 11 (4) ◽  
pp. 6589-6594
Author(s):  
Anand Vijaya Kumar P R ◽  
Kokul Rajan P ◽  
Seema A ◽  
Balashanmugam K

Diabetes is a chronic disease that occurs either when the pancreas does not produce enough insulin or when the body cannot effectively use the insulin it produces. Type 2 diabetes results from the body’s ineffective use of insulin. Type 2 diabetes comprises most people with diabetes around the world and is associated with various complications such as diabetic , , nephropathy, cardio vascular diseases, depression, dementia, sexual dysfunction etc. classified as , or blue-green algae which has been used for centuries as a food source in other countries. is also being promoted to prevent, treat, or cure several conditions, including high cholesterol, hypertension, diabetes, depression, viral hepatitis, and malnutrition. A few assertions have been tested, but most trials have been small, poorly designed, or inconclusive. Statins suppress the enzyme HMG-CoA reductase via pathway. The health advantage of HMG-CoA reductase inhibitors is believed to expand behind their cholesterol lowering effects. Such effects of statins incorporate complimentary effects on endothelial function, systemic inflammation and oxidative stress. The above-mentioned effects were predicted to decrease the risk of diabetes, even though statins are supported by most patients, some study suggested it is affiliated with new onset of diabetes . Despite dispute discoveries, many studies suggest that different statins may relay distinct possibility of diabetes. The problem is, there's little or no scientific evidence to back up such claims. this review is under taken to the potential benefits if and statin in management of type 2 diabetes and its complications. Many previous studies were thoroughly, and it was found that combination of and statin is found to reduce the diabetes and its complications.

Author(s):  
Masataka Kusunoki ◽  
Takahiko Sakazaki ◽  
Kazuhiko Tsutsumi ◽  
Tetsuro Miyata ◽  
Yoshiharu Oshida

Objective: The combination therapy of HMG-CoA reductase inhibitors (statins), which are anti-hyperlipidemia agents, and fibrates may increase the risk of hepatic dysfunction and myopathy, so this combination required careful administration for patients. In the present study, we evaluated the effects of combination therapy of pemafibrate, a novel fibrate and statins. Methods: We administered pemafibrate for 6 months as an add-on to statin therapy in 27 type 2 diabetes patients with dyslipidemia already receiving statins for 6 months (combination group), and examined the efficacy and safety of the combination therapy in comparison with a pemafibrate monotherapy group. Results: In the combination group, decrease in serum total cholesterol levels was observed after 6 months of pemafibrate treatment compared to baseline, along with increase in HDL-cholesterol. While serum triglyceride level reduced, HbA1c level was elevated in both the groups. Serum creatinine kinase level, which is an indicator of myopathy, was lowered in the combination group. In addition, decrease in -glutamyl transpeptidase, a parameter of hepatic dysfunction, was observed in the combination group. Conclusion: The statin-pemafibrate combination therapy in type 2 diabetes patients with dyslipidemia improved lipid metabolism safely without increasing the risk of hepatic dysfunction and myopathy.


2000 ◽  
Vol 85 (3) ◽  
pp. 1137-1142 ◽  
Author(s):  
Yoon-Sok Chung ◽  
Mi-Deok Lee ◽  
Seong-Kyu Lee ◽  
Hyeon-Man Kim ◽  
Lorraine A. Fitzpatrick

Sign in / Sign up

Export Citation Format

Share Document